Last reviewed · How we verify

Mydriacyl Ophthalmic Product

Mantis Photonics AB · Phase 1 active Small molecule

Mydriacyl Ophthalmic Product is a Small molecule drug developed by Mantis Photonics AB. It is currently in Phase 1 development.

At a glance

Generic nameMydriacyl Ophthalmic Product
SponsorMantis Photonics AB
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mydriacyl Ophthalmic Product

What is Mydriacyl Ophthalmic Product?

Mydriacyl Ophthalmic Product is a Small molecule drug developed by Mantis Photonics AB.

Who makes Mydriacyl Ophthalmic Product?

Mydriacyl Ophthalmic Product is developed by Mantis Photonics AB (see full Mantis Photonics AB pipeline at /company/mantis-photonics-ab).

What development phase is Mydriacyl Ophthalmic Product in?

Mydriacyl Ophthalmic Product is in Phase 1.

Related